Pfizer has entered into a licensing agreement valued at approximately US$6 billion (RM25.74 billion) with Chinese biopharmaceutical company 3SBio Inc, advancing a strategic collaboration for the development, manufacturing, and commercialisation of a cancer treatment currently under clinical evaluation.
The agreement centres on SSGJ-707, a drug candidate undergoing multiple clinical trials in China for the treatment of non-small cell lung cancer, metastatic colorectal cancer, and gynaecological tumours. 3SBio is expected to initiate the first Phase III trial of the compound in China later this year.
In a separate statement, 3SBio confirmed that SSGJ-707 has secured Investigational New Drug (IND) clearance from the United States Food and Drug Administration, a key regulatory milestone supporting further clinical development.
As part of the agreement, 3SBio and its subsidiaries will grant Pfizer global rights to SSGJ-707, excluding the Chinese market. The deal includes an option for Pfizer to obtain commercialisation rights within China at a later stage.
Pfizer has announced that it will manufacture the drug substance for SSGJ-707 at its facility in Sanford, North Carolina, while the drug product will be produced in McPherson, Kansas. Additionally, Pfizer intends to make a US$100 million equity investment in 3SBio upon the close of the transaction, which is anticipated to be completed in the third quarter of 2025.
-Reuters
